Windward Bio gets $165M to take China-derived drug into Phase 3 asthma trial

Luca Santarelli, Windward Bio CEO May 4, 2026 09:03 AM EDT FinancingStartupsChina Wind­ward Bio gets $165M to take Chi­na-de­rived drug in­to Phase 3 asth­ma tri­al Kyle LaHucik Biotech Correspondent A Swiss biotech with two ex­per­i­men­tal med­i­cines from Chi­na, plus an in-house dis­cov­ery team, has brought in $165 mil­lion to ad­vance in­to late-stage test­ing. The … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER